1.       The Canadian Institutes of Health Research continue to fund research promoting the development, implementation and evaluation of e‑health tools in Canada.

2.       The Government of Canada and Canada Health Infoway Inc. focus its investments on the development of e-health tools that engage patients in their own care.

3.       The Government of Canada continue to fund Health Canada’s e-Health Infostructure Program.

4.       Health Canada, through its e‑Health Infostructure Program, continue to ensure that remote and northern First Nations and Inuit communities have sufficient access to broadband networks.

5.       Canada Health Infoway Inc. continue to work with Health Canada, First Nations, Inuit communities and provincial governments to address jurisdictional challenges in the development and implementation of e-health and telehealth systems.

6.       Health Canada, in partnership with First Nations and Inuit communities, provincial and territorial governments, and other relevant stakeholders, consider promoting the adoption of telerobotic systems in northern and remote communities where feasible.

7.       Health Canada continue to identify efficiencies to reduce the burden that the regulatory system places on small- and medium-sized enterprises producing medical devices.

8.       Health Canada continue its efforts to harmonize the regulatory system for pharmaceutical drugs and medical devices with those of other jurisdictions.

9.       Health Canada ensure that its regulatory framework for pharmaceuticals and medical devices is responsive to developments in genomics, personalized medicine and nanotechnology.

10.    The Canadian Agency for Drugs and Technologies in Health work with health technology assessment organizations across Canada to coordinate their activities and share best practices.

11.    The Government of Canada continue to provide support for new models of drug development, such as the Structural Genomics Consortium.

12.    The Government of Canada maintain its support for genomic sequencing infrastructure in Canada through the Canada Foundation for Innovation.

13.    The Government of Canada continue to support nanotechnology research.

14.    Health Canada, in addition to its support of Orphanet, participate in and contribute to international rare disease registries to facilitate international cooperation on the treatment of rare diseases.

15.    Canadian Institutes for Health Research and the Public Health Agency of Canada, in collaboration with the Networks of Centres of Excellence, consider identifying clusters of rare disease research in Canada, and consider formalizing some of them as Centres of Excellence within the Network.

16.    Health Canada consider whether it is necessary to establish a framework for non-pharmaceutical treatments such as medical devices used to treat rare diseases in the orphan drug framework or whether it is necessary to create a parallel framework for non-pharmaceutical treatments.

17.    The Public Health Agency of Canada and the Canadian Institutes for Health Research consider ways to facilitate the sharing of best practices among industry, researchers and clinicians with respect to technological innovations in chronic disease prevention and management.

18.    Health Canada and the Public Health Agency of Canada continue to promote health literacy with a view to empowering patients to take steps to prevent and manage chronic illness.

19.    Health Canada review its requirements for the regulation of medical devices to ensure that it is receiving sufficient data that takes into account the short- and long-term health outcomes of patients.

20.    The Government of Canada continue to fund research and development activities in order to promote technological innovation in health care in Canada.

21.    The Government of Canada continue to fund not-for-profit public-private partnerships focused on the commercialization of health research through its Networks of Excellence of Canada Program.

22.    The Government of Canada take note of the innovative models of health care delivery outlined in this section of the report.